ENTA

SEC source: 0001177648-18-000028 · edgar.xml · nonDerivative · entry 3

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,258

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $114.55 to $115.51, inclusive.

SEC source: 0001177648-18-000028 · edgar.xml · nonDerivative · entry 2

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,487

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $113.44 to $114.28, inclusive.

SEC source: 0001177648-18-000028 · edgar.xml · nonDerivative · entry 1

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,755

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-18-000029 · edgar.xml · derivative · entry 2

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,960 shares

Expires 2018-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-18-000029 · edgar.xml · nonDerivative · entry 1

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,418

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-18-000027 · edgar.xml · nonDerivative · entry 5

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,458

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2018.

F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $121.995 to $122.39, inclusive.

SEC source: 0001177648-18-000027 · edgar.xml · nonDerivative · entry 4

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,069

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2018.

F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $120.95 to $121.90, inclusive.

SEC source: 0001177648-18-000027 · edgar.xml · nonDerivative · entry 3

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,222

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2018.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $119.925 to $120.83, inclusive.

SEC source: 0001177648-18-000027 · edgar.xml · nonDerivative · entry 2

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,558

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2018.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $118.92 to $119.89, inclusive.

SEC source: 0001177648-18-000027 · edgar.xml · nonDerivative · entry 1

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,158

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2018.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $117.51 to $117.55, inclusive.

SEC source: 0001177648-18-000026 · edgar.xml · nonDerivative · entry 2

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 628,026

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.75 to $106.35, inclusive.

SEC source: 0001177648-18-000024 · edgar.xml · derivative · entry 5

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,090

Underlying: Common Stock · 2,955 shares

Expires 2025-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date.

SEC source: 0001177648-18-000024 · edgar.xml · nonDerivative · entry 4

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,800

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.01 to $106.00, inclusive.

SEC source: 0001177648-18-000024 · edgar.xml · nonDerivative · entry 3

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,755

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.47 to $104.95, inclusive.

SEC source: 0001177648-18-000024 · edgar.xml · nonDerivative · entry 2

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,555

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $103.64 to $103.96, inclusive.

SEC source: 0001177648-18-000024 · edgar.xml · nonDerivative · entry 1

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,955

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-18-000026 · edgar.xml · nonDerivative · entry 1

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 638,994

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.75 to $106.00, inclusive.

SEC source: 0001177648-18-000022 · edgar.xml · derivative · entry 4

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,045

Underlying: Common Stock · 2,955 shares

Expires 2025-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date.

SEC source: 0001177648-18-000022 · edgar.xml · nonDerivative · entry 3

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $85.47 to $86.45, inclusive.

SEC source: 0001177648-18-000022 · edgar.xml · nonDerivative · entry 2

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,425

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.45, inclusive.

SEC source: 0001177648-18-000022 · edgar.xml · nonDerivative · entry 1

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,225

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-18-000020 · edgar.xml · nonDerivative · entry 4

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,458

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in February 2018.

F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $87.87 to $88.00, inclusive.

SEC source: 0001177648-18-000020 · edgar.xml · nonDerivative · entry 3

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,658

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in February 2018.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.80 to $87.78, inclusive.

SEC source: 0001177648-18-000020 · edgar.xml · nonDerivative · entry 2

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,558

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in February 2018.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $85.65 to $86.57, inclusive.

SEC source: 0001177648-18-000020 · edgar.xml · nonDerivative · entry 1

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,458

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in February 2018.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.53 to $85.43, inclusive.

SEC source: 0001177648-18-000019 · edgar.xml · derivative · entry 1

Vance Terry · CIK 0001572282 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2028-02-28

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2018), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2019 annual meeting of stockholders.

SEC source: 0001177648-18-000017 · edgar.xml · derivative · entry 1

Russell Lesley · CIK 0001374636 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2028-02-28

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2018), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2019 annual meeting of stockholders.

SEC source: 0001177648-18-000015 · edgar.xml · derivative · entry 1

Peterson Kristine · CIK 0001508596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,750

Underlying: Common Stock · 3,750 shares

Expires 2028-02-28

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2018), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2019 annual meeting of stockholders.

SEC source: 0001177648-18-000013 · edgar.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2028-02-28

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2018), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2019 annual meeting of stockholders.

SEC source: 0001177648-18-000011 · edgar.xml · derivative · entry 1

CARTER BRUCE L A · CIK 0001225503 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2028-02-28

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2018), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2019 annual meeting of stockholders.

SEC source: 0001177648-18-000009 · edgar.xml · derivative · entry 1

Buckley Stephen Jr. · CIK 0001571830 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2028-02-28

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2018), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2019 annual meeting of stockholders.

SEC source: 0001177648-18-000007 · edgar.xml · nonDerivative · entry 3

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,270

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001177648-18-000007 · edgar.xml · nonDerivative · entry 2

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,836

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 21, 2015 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2018.

SEC source: 0001177648-18-000007 · edgar.xml · nonDerivative · entry 1

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,808

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 21, 2015 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2018.

SEC source: 0001177648-18-000006 · edgar.xml · nonDerivative · entry 3

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,327

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001177648-18-000006 · edgar.xml · nonDerivative · entry 2

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,392

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 21, 2015 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2018.

SEC source: 0001177648-18-000006 · edgar.xml · nonDerivative · entry 1

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,570

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 21, 2015 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2018.

SEC source: 0001177648-18-000005 · edgar.xml · nonDerivative · entry 3

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 653,026

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001177648-18-000005 · edgar.xml · nonDerivative · entry 2

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 664,158

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 21, 2015 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2018.

SEC source: 0001177648-18-000005 · edgar.xml · nonDerivative · entry 1

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 643,421

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 21, 2015 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2018.

SEC source: 0001177648-18-000004 · edgar.xml · nonDerivative · entry 3

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,458

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001177648-18-000004 · edgar.xml · nonDerivative · entry 2

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,825

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 21, 2015 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2018.

SEC source: 0001177648-18-000004 · edgar.xml · nonDerivative · entry 1

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,279

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 21, 2015 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2018.

SEC source: 0001177648-18-000003 · edgar.xml · nonDerivative · entry 3

Ocain Tim · CIK 0001599020 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,127

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001177648-18-000003 · edgar.xml · nonDerivative · entry 2

Ocain Tim · CIK 0001599020 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,192

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 21, 2015 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2018.

SEC source: 0001177648-18-000003 · edgar.xml · nonDerivative · entry 1

Ocain Tim · CIK 0001599020 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,370

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 21, 2015 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2018.

SEC source: 0001177648-18-000002 · edgar.xml · nonDerivative · entry 3

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 309,920

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001177648-18-000002 · edgar.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 312,586

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 21, 2015 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2018.

SEC source: 0001177648-18-000002 · edgar.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 306,317

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 21, 2015 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2018.

SEC source: 0001177648-18-000001 · edgar.xml · derivative · entry 2

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,200

Underlying: Common Stock · 4,300 shares

Expires 2024-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option to purchase a total of 82,500 shares of common stock became exercisable with respect to twenty-five percent (25%) of the shares on May 9, 2015 (the "Anniversary Date"), with the remainder becoming exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years from the Anniversary Date.